ES2523119T3 - Nanocristales de monohidrato de calcipotriol - Google Patents

Nanocristales de monohidrato de calcipotriol Download PDF

Info

Publication number
ES2523119T3
ES2523119T3 ES10803440.6T ES10803440T ES2523119T3 ES 2523119 T3 ES2523119 T3 ES 2523119T3 ES 10803440 T ES10803440 T ES 10803440T ES 2523119 T3 ES2523119 T3 ES 2523119T3
Authority
ES
Spain
Prior art keywords
nanocrystals
calcipotriol monohydrate
fifty
calcipotriol
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10803440.6T
Other languages
English (en)
Spanish (es)
Inventor
Karsten Petersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of ES2523119T3 publication Critical patent/ES2523119T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10803440.6T 2009-12-22 2010-12-22 Nanocristales de monohidrato de calcipotriol Active ES2523119T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK2009000267 2009-12-22
WOPCT/DK2009/000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
US293091P 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (1)

Publication Number Publication Date
ES2523119T3 true ES2523119T3 (es) 2014-11-21

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10803440.6T Active ES2523119T3 (es) 2009-12-22 2010-12-22 Nanocristales de monohidrato de calcipotriol

Country Status (15)

Country Link
US (2) US20130039952A1 (enExample)
EP (1) EP2515874B1 (enExample)
JP (1) JP5816194B2 (enExample)
CN (1) CN102770125B (enExample)
AU (1) AU2010335655B2 (enExample)
BR (1) BR112012015449B1 (enExample)
CA (1) CA2785253A1 (enExample)
ES (1) ES2523119T3 (enExample)
IL (1) IL220516A (enExample)
MX (1) MX2012007234A (enExample)
NZ (1) NZ601000A (enExample)
PL (1) PL2515874T3 (enExample)
RU (1) RU2555339C2 (enExample)
WO (1) WO2011076208A2 (enExample)
ZA (1) ZA201204618B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918369C (en) * 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
KR20190042558A (ko) 2016-07-05 2019-04-24 크라토스 엘엘씨 부동태화된 예비리튬화된 마이크론 및 서브마이크론 iva족 입자 및 이의 제조방법
US11637280B2 (en) 2017-03-31 2023-04-25 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
JP7751298B2 (ja) * 2021-07-14 2025-10-08 株式会社ツツミプランニング 浸透深さの調整方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
PL212660B1 (pl) * 2000-10-27 2012-11-30 Leo Pharma As Zasadniczo niewodna zelowa kompozycja farmaceutyczna do podawania na skóre oraz jej zastosowanie
EP1339390A2 (en) * 2000-12-06 2003-09-03 Pharmacia Corporation Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
CA2530302C (en) 2003-07-24 2013-12-03 Leo Pharma A/S Novel aminobenzophenone compounds
EP1742612A2 (en) * 2004-05-06 2007-01-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
ES2341473T3 (es) 2004-12-13 2010-06-21 Leo Pharma A/S Compuestos de aminobenzofenona sustituida con triazol.
ES2447301T3 (es) * 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited Formulación vitamínica
WO2007050543A2 (en) * 2005-10-24 2007-05-03 Collegium Pharmaceutical, Inc. Topical pharmaceutical foam composition
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
HRP20110464T1 (hr) 2006-12-22 2011-07-31 Leo Pharma A/S Supstituirani acetofenoni korisni kao inhibitori pde4
SI2114951T1 (sl) 2007-02-28 2014-08-29 Leo Pharma A/S Novi zaviralci fosfodiesteraze
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
EP2146780A1 (en) 2007-05-11 2010-01-27 Sonneborn Inc. Petrolatums having silicone-like properties
WO2010069322A1 (en) 2008-12-19 2010-06-24 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Also Published As

Publication number Publication date
JP5816194B2 (ja) 2015-11-18
AU2010335655A1 (en) 2012-07-19
NZ601000A (en) 2014-07-25
JP2013515019A (ja) 2013-05-02
CA2785253A1 (en) 2011-06-30
BR112012015449B1 (pt) 2021-09-28
CN102770125B (zh) 2015-02-11
HK1177694A1 (en) 2013-08-30
RU2555339C2 (ru) 2015-07-10
US20140322331A1 (en) 2014-10-30
MX2012007234A (es) 2012-07-30
EP2515874A2 (en) 2012-10-31
CN102770125A (zh) 2012-11-07
US20130039952A1 (en) 2013-02-14
IL220516A (en) 2015-06-30
ZA201204618B (en) 2013-09-25
AU2010335655B2 (en) 2015-03-05
EP2515874B1 (en) 2014-08-20
WO2011076208A2 (en) 2011-06-30
PL2515874T3 (pl) 2015-01-30
RU2012130412A (ru) 2014-01-27
WO2011076208A3 (en) 2012-03-01
BR112012015449A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
ES2523119T3 (es) Nanocristales de monohidrato de calcipotriol
DK2506830T3 (en) An ophthalmic emulsion
ES2482090T3 (es) Procedimiento de preparación de nano-emulsiones
JP6368834B2 (ja) スクリーンフォーマー用の外用組成物
EA026697B1 (ru) Трансдермальные композиции ибупрофена и способы их применения
CZ20023005A3 (cs) Nový samoemulgační systém pro podávání léčiva
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
RU2012130421A (ru) Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
CN104602670A (zh) 含有ω-3 脂肪酸的眼用组合物
TW201622705A (zh) 包含度他雄胺之用於自發性乳化藥物傳輸系統的組合物
UA79267C2 (en) Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation
ES2576740T3 (es) Composiciones farmacéuticas tópicas que incluyen REL-N-[6-[(2R,6S)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida
ES2749008T3 (es) Formulaciones estables de undecanoato de testosterona
CA3163530A1 (en) Topical composition comprising tofacitinib and fingolimod
CA3086977C (en) Lipid-based ophthalmic emulsion
TWI342774B (en) Semi-solid formulations for the oral administration of taxoids
CN105796489A (zh) 一种布洛芬注射液
CN104288092A (zh) 拉坦前列素滴眼剂
CN104274826A (zh) 一种水包油型复方粘菌素纳米乳
JP5840668B2 (ja) ロキソプロフェンナトリウム含有軟カプセル用内容物、及び、それを含有する軟カプセル製剤
CN102302448A (zh) 一种水包油型呋喃唑酮纳米乳抗菌药物及其制备方法
JP2011084521A (ja) アゼラスチン塩酸塩含有カプセル剤
ES2354278T3 (es) Formulación farmaceutica de nitroxiderivado de aines.
JP2017057202A (ja) ボルテゾミブ含有凍結乾燥医薬組成物およびその製造方法
WO2008050844A1 (en) Composition for external application to skin and skin regeneration promoter